Linezolid (LZD) is a recommended antibiotic drug for the treatment of deep skin infections in diabetic conditions. However, the application of LZD is limited to indefinite drug release topically. The aim of this study was to develop and characterize a novel LZD loaded ethosomes and compare with LZD loaded liposomes and hydroethanolic drug solution for topical delivery to provide safe and effective treatment against skin infections during diabetes. In this study, the LZD loaded ethosomes was prepared by cold method. It was compared with liposomes and hydroethanolic solution of linezolid, and characterized for particle size, shape, polydispersity, entrapment efficiency and zeta potential. In vitro release profile was determined by dialysis bag and skin penetration effect was evaluated using Franz diffusion cell. In vivo skin irritation test was performed using animal skin. Animals were made diabetic by administering Streptozotocin intraperitonealy. Antimicrobial activity against Staphylococcus aureus was determined by using cup plate method and also checked on animals. The results showed that among all formulations LZD loaded ethosomes had better entrapment efficiency (67.32%), polydispersity (0.21), spherical shape, size (299.86 nm), zeta potential (-44.2 mV) and highest in vitro release (98 ± 1.5% in 48 h) and drug permeation (46.6±1.6% % within 24 h). Low irritation score (0.72) revealed that ethosomes was non-irritant. Antimicrobial assay indicated that linezolid loaded ethosomes had better inhibitory effect against S. aureus and prevented deep skin infections. LZD loaded ethosomes was found more effective in treatment of skin and soft tissue infections in comparison to convectional liposomes and hydroethanolic drug solution. It may be an ideal drug formulation for treating deep skin infections during diabetes due to its better skin retention property and lesser side effects.
Cite this article:
Suresh K. Sahu, Alpana Ram.Evaluation of Linezolid Loaded Ethosomes for Treatment of Deep Skin Infections in Diabetic Model. Research J. Pharm. and Tech 2018; 11(7): 3023-3030. doi: 10.5958/0974-360X.2018.00557.7